Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Gilead Sciences : Chief Scientific Officer John McHutchison to Leave

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/17/2019 | 09:10am EST

By Colin Kellaher

Gilead Sciences Inc. (GILD) on Wednesday said three executives, including its top researcher, will be leaving the biopharmaceutical company.

Gilead said John McHutchison is stepping down as chief scientific officer and head of research and development, effective Aug. 2.

The Foster City, Calif., company said it will immediately commence a search for his successor.

Mr. McHutchison, who joined Gilead in 2010 and has been chief scientific officer since March 2018, will receive a lump-sum payment of $1.1 million as part of a transition agreement, the company said.

Separately, Gilead said Chief Patient Officer Gregg Alton and Katie Watson, executive vice president of human resources, will also be leaving the company.

Mr. Alton, who joined Gilead in 1999, will remain through Oct. 4 and will serve as an adviser until the end of the year to help transition his duties to other parts of the company.

Gilead said Jyoti Mehra, who joined the company in 2017 as vice president of human resources, will succeed Ms. Watson as executive vice president of human resources, effective Aug. 5.

Ms. Watson, who joined Gilead in 2003, will leave on Sept. 1 but will advise on the transition through the end of the year, Gilead said.

Write to Colin Kellaher at colin.kellaher@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
11/12GILEAD SCIENCES : Report
CO
11/11GILEAD SCIENCES : New Data on Filgotinib in Rheumatoid Arthritis Demonstrate Dur..
AQ
11/11GILEAD SCIENCES : Data Showing Potential for Machine Learning to Advance Underst..
AQ
11/11GILEAD SCIENCES : Announces New Data from Viral Hepatitis Research Programs at T..
AQ
11/11GILEAD SCIENCES : Presents Data on Investigational HIV-1 Capsid Inhibitor GS-620..
AQ
11/08GILEAD SCIENCES : Did You Invest in Gilead Sciences?
BU
11/08GILEAD SCIENCES : Presents Data on Investigational HIV-1 Capsid Inhibitor GS-620..
BU
11/08GILEAD SCIENCES : Data Showing Potential for Machine Learning to Advance Underst..
BU
11/08GILEAD SCIENCES : Announces New Data from Viral Hepatitis Research Programs at T..
BU
11/07GILEAD SCIENCES : United States sues Gilead for patent violation on HIV preventi..
AQ
More news
Financials (USD)
Sales 2019 22 290 M
EBIT 2019 11 488 M
Net income 2019 4 319 M
Finance 2019 2 986 M
Yield 2019 3,86%
P/E ratio 2019 18,2x
P/E ratio 2020 11,6x
EV / Sales2019 3,56x
EV / Sales2020 3,45x
Capitalization 82 323 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 78,00  $
Last Close Price 65,07  $
Spread / Highest target 46,0%
Spread / Average Target 19,9%
Spread / Lowest Target -7,79%
EPS Revisions
Managers
NameTitle
Daniel O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Gayle Edlund Wilson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES4.03%82 323
VERTEX PHARMACEUTICALS26.61%53 950
REGENERON PHARMACEUTICALS-7.67%37 702
WUXI APPTEC CO., LTD.81.65%22 459
GENMAB41.12%14 493
BEIGENE, LTD.41.34%12 019